Literature DB >> 21688119

Natural resistance to apoptosis correlates with resistance to chemotherapy in colorectal cancer cells.

Yan Zhang1, Jia Yuan, Hong Yan Zhang, Dilixia Simayi, Pin Dong Li, Ying Hong Wang, Feng Li, Wen Jie Zhang.   

Abstract

Defects in apoptotic machinery vary among individual cancer cells, and the efficacy of chemotherapy in killing cancer cells depends on the successful induction of apoptosis. This study tested the hypothesis that the intrinsic ability of a cancer cell's natural resistance to apoptosis would indicate its ability in resistance to chemotherapy. Four widely studied human colorectal cancer cell lines, SW480, HT-29, LoVo and Caco-2, were examined for their apoptotic fates in spontaneous cultures for up to 6 days using flowcytometry. Chemoresponse of these cells was tested against anti-colorectal cancer drugs 5-fluorouracil (5-FU) and oxaliplatin (OXP) at different peak plasma concentrations (PPCs) using MTT assay. Apoptosis analyses demonstrated that, from Day 2 to Day 6 in spontaneous cultures, SW480 and HT-29 lines showed resistance to apoptosis by having much less average early and late apoptotic cells than LoVo and Caco-2 lines with differences of 3.2- to 5.2-fold. Interestingly, apoptosis-resistant SW480 and HT-29 exhibited higher chemoresistance to both 5-FU (P < 0.01 at 5×, 10×, and 50× PPC) and OXP (P < 0.01 at 5× and 10× PPC, and P < 0.05 at 50× PPC) than LoVo and Caco-2. Colorectal cancer cells' natural resistance to apoptosis is an intrinsic ability that correlates with resistance to chemotherapeutic drugs 5-FU and OXP. Cancer cells' natural apoptotic phenotypes may help predict the outcome of chemotherapy in colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21688119     DOI: 10.1007/s10238-011-0146-5

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  24 in total

1.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 2.  Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment.

Authors:  Salvador Rodriguez-Nieto; Boris Zhivotovsky
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

3.  In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.

Authors:  E Klumper; R Pieters; G J Kaspers; D R Huismans; A H Loonen; M M Rottier; E R van Wering; A van der Does-van den Berg; K Hählen; U Creutzig
Journal:  Leukemia       Date:  1995-11       Impact factor: 11.528

4.  IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells.

Authors:  Wen Jie Zhang; Ben Hui Li; Xian Zi Yang; Pin Dong Li; Qin Yuan; Xiao Hong Liu; Shuang Bing Xu; Yan Zhang; Jia Yuan; Glenn S Gerhard; Kathryn K Masker; Cheng Dong; Walter A Koltun; Michael J Chorney
Journal:  Cytokine       Date:  2008-03-14       Impact factor: 3.861

5.  Comparison of in vitro anticancer chemosensitivity between human squamous cell carcinoma and adenocarcinoma.

Authors:  T Kusumoto; Y Sakaguchi; Y Maehara; T Nakashima; M Furusawa; K Sugimachi
Journal:  Oncology       Date:  1992       Impact factor: 2.935

6.  IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells.

Authors:  Ben Hui Li; Xian Zi Yang; Pin Dong Li; Qin Yuan; Xiao Hong Liu; Jia Yuan; Wen Jie Zhang
Journal:  Biochem Biophys Res Commun       Date:  2008-02-21       Impact factor: 3.575

7.  Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line.

Authors:  M C Grès; B Julian; M Bourrié; V Meunier; C Roques; M Berger; X Boulenc; Y Berger; G Fabre
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

Review 8.  Apoptotic pathways in tumor progression and therapy.

Authors:  Armelle Melet; Keli Song; Octavian Bucur; Zainab Jagani; Alexandra R Grassian; Roya Khosravi-Far
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

9.  DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells.

Authors:  Sandrine Faivre; Denise Chan; Richard Salinas; Barbara Woynarowska; Jan M Woynarowski
Journal:  Biochem Pharmacol       Date:  2003-07-15       Impact factor: 5.858

10.  In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood.

Authors:  G J Kaspers; R Pieters; C H Van Zantwijk; P A De Laat; F C De Waal; E R Van Wering; A J Veerman
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

View more
  6 in total

Review 1.  Patient-derived xenograft models for personalized medicine in colorectal cancer.

Authors:  Jun Xie; Yan Lin
Journal:  Clin Exp Med       Date:  2020-02-25       Impact factor: 3.984

2.  Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.

Authors:  Yong Huang; Haijun Yu; Han Lei; Conghua Xie; Yahua Zhong
Journal:  Med Oncol       Date:  2014-01-28       Impact factor: 3.064

3.  DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner.

Authors:  Sepideh Razi; Asieh Sadeghi; Zeynab Asadi-Lari; Kevin J Tam; Elham Kalantari; Zahra Madjd
Journal:  Clin Exp Med       Date:  2020-09-23       Impact factor: 3.984

4.  5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer.

Authors:  Raúl Ortiz; José Prados; Consolación Melguizo; José L Arias; M Adolfina Ruiz; Pablo J Alvarez; Octavio Caba; Raquel Luque; Ana Segura; Antonia Aránega
Journal:  Int J Nanomedicine       Date:  2012-01-09

5.  The BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce apoptosis by suppressing cyclin-A2/Akt/FOXO3a signaling.

Authors:  Gao-Xiang Zhao; Li-Hui Xu; Hao Pan; Qiu-Ru Lin; Mei-Yun Huang; Ji-Ye Cai; Dong-Yun Ouyang; Xian-Hui He
Journal:  Oncotarget       Date:  2015-11-17

6.  IFI30 Is a Novel Immune-Related Target with Predicting Value of Prognosis and Treatment Response in Glioblastoma.

Authors:  Chen Zhu; Xin Chen; Gefei Guan; Cunyi Zou; Qing Guo; Peng Cheng; Wen Cheng; Anhua Wu
Journal:  Onco Targets Ther       Date:  2020-02-05       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.